ReviewFrontiers in immunology2016
Cross-Reactivity of TCR Repertoire: Current Concepts, Challenges, and Implication for Allotransplantation.
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Computational prediction of TCR cross-reactivity: principles, challenges and translational opportunities.Journal of translational medicine · 2026Review
- Strengths and limitations of web servers for the modeling of TCRpMHC complexes.Computational and structural biotechnology journal · 2024Article
- Editorial: Quantification and prediction of T-cell cross-reactivity through experimental and computational methods.Frontiers in immunology · 2024Article
- Lowering maintenance immune suppression in elderly kidney transplant recipients; connecting the immunological and clinical dots.Frontiers in medicine · 2023Review
- Single-cell RNA-seq revealing the immune features of donor liver during liver transplantation.Frontiers in immunology · 2023Article
- CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases.Frontiers in immunology · 2023Article
- Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma.Frontiers in immunology · 2022Article
- Critical role of the CD44Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- A Comparison ofFrontiers in immunology · 2021Article
- HLA-Arena: A Customizable Environment for the Structural Modeling and Analysis of Peptide-HLA Complexes for Cancer Immunotherapy.JCO clinical cancer informatics · 2020Article
- Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation.Leukemia · 2020Article
- CD8+ T-Cell Repertoire in Human Leukocyte Antigen Class I-Mismatched Alloreactive Immune Response.Frontiers in immunology · 2020Article
- Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors.Frontiers in immunology · 2020Review
- T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation.Immuno-oncology technology · 2019Review
- APE-Gen: A Fast Method for Generating Ensembles of Bound Peptide-MHC Conformations.Molecules (Basel, Switzerland) · 2019Article
- Foxp3Frontiers in immunology · 2019Article
- Exploring the pre-immune landscape of antigen-specific T cells.Genome medicine · 2018Article
- Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- General Prediction of Peptide-MHC Binding Modes Using Incremental Docking: A Proof of Concept.Scientific reports · 2018Article
- Structure-based Methods for Binding Mode and Binding Affinity Prediction for Peptide-MHC Complexes.Current topics in medicinal chemistry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Being able to track donor reactive T cells during the course of organ transplantation is a key to improve the graft survival, to prevent graft dysfunction, and to adapt the immunosuppressive regimen. The attempts of transplant immunologists have been for long hampered by the large size of the alloreactive T cell repertoire. Understanding how self-TCR can interact with allogeneic MHC is a key to critically appraise the different assays available to analyze the TCR Vβ repertoire usage. In this report, we will review conceptually and experimentally the process of cross-reactivity. We will then highlight what can be learned from allotransplantation, a situation of artificial cross-reactivity. Finally, the low- and high-resolution techniques to characterize the TCR Vβ repertoire usage in transplantation will be critically discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.